AstraZeneca targets $1.5 billion in annual savings to fund its pipeline
The restructuring programme carries up to $2 billion in one-time costs. Third-quarter revenue rose 7%, and the drugmaker kept its full-year guidance.
AstraZeneca announced a restructuring programme designed to deliver $1.5 billion in annualised pre-tax savings, with the money reinvested mainly in its drug pipeline. The company expects up to $2 billion in one-time restructuring costs and says the work should be essentially complete by the end of 2029.
The programme, called Reshaping for Sustainable Growth, will redeploy resources and build capabilities across the business. AstraZeneca has more than 180 pipeline projects. It did not specify whether the programme would include job cuts, according to Reuters.
Savings and costs are different measures
The $1.5 billion target is an annualised run-rate benefit, not a promise of that much extra profit immediately. The up-to-$2 billion figure is the programme's expected one-time cost. Neither should be confused with revenue from a new medicine.
AstraZeneca says the savings will be reinvested, principally in the pipeline. The stated purpose is to create room for development spending, rather than to pass the full saving straight through to earnings.
Quarterly growth, unchanged annual outlook
Third-quarter revenue was $16.209 billion, up 7% both at actual exchange rates and at constant exchange rates. Reported earnings were $2.02 a share, while core earnings were $2.79 a share. Core earnings exclude certain items and are not the same measure as reported earnings.
Reuters reported that revenue and core earnings exceeded analysts' forecasts. Growth in cancer and rare-disease medicines helped offset pressure on older products facing generic competition.
AstraZeneca kept its 2026 guidance: revenue growth in a mid-to-high single-digit percentage range and core earnings-per-share growth in a low double-digit percentage range, both at constant exchange rates. Constant-currency guidance strips out exchange-rate movements; it is not a forecast of identical growth in reported dollars.
The results and restructuring plan answer different questions. The quarter shows the current commercial performance, while the savings programme is meant to support future development. Whether that investment produces successful medicines remains dependent on clinical and regulatory outcomes.
